G. Despotis, M. Avidan, C. Hogue, and . Jr, Mechanisms and attenuation of hemostatic activation during extracorporeal circulation, The Annals of Thoracic Surgery, vol.72, issue.5, pp.1821-1831, 2001.
DOI : 10.1016/S0003-4975(01)03211-8

J. Levy, Pharmacologic preservation of the hemostatic system during cardiac surgery, The Annals of Thoracic Surgery, vol.72, issue.5
DOI : 10.1016/S0003-4975(01)03218-0

L. Dacey, J. Munoz, Y. Baribeau, E. Johnson, S. Lahey et al., Reexploration for Hemorrhage Following Coronary Artery Bypass Grafting<subtitle>Incidence and Risk Factors</subtitle>, Archives of Surgery, vol.133, issue.4, pp.442-447, 1998.
DOI : 10.1001/archsurg.133.4.442

M. Moulton, L. Creswell, M. Mackey, J. Cox, and M. Rosenbloom, Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations, The Journal of Thoracic and Cardiovascular Surgery, vol.111, issue.5, pp.1037-1046, 1996.
DOI : 10.1016/S0022-5223(96)70380-X

P. Diprose, M. Herbertson, O. Shaughnessy, D. Deakin, C. Gill et al., Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage, British Journal of Anaesthesia, vol.94, issue.3, pp.271-278, 2005.
DOI : 10.1093/bja/aei044

R. Gill, M. Herbertson, A. Vuylsteke, P. Olsen, C. Von-heymann et al., Safety and Efficacy of Recombinant Activated Factor VII: A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery, Circulation, vol.120, issue.1, pp.21-28, 2009.
DOI : 10.1161/CIRCULATIONAHA.108.834275

T. Athanasiou, Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review

M. Aldouri, The Use of Recombinant Factor VIIa in Controlling Surgical Bleeding in Non-Haemophiliac Patients, Pathophysiology of Haemostasis and Thrombosis, vol.32, issue.1, pp.41-46, 2002.
DOI : 10.1159/000057301

C. Sawchuk, S. Wang, T. Waters, B. Wong, and T. Yau, Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery, Circulation, vol.118, pp.331-338, 2008.

F. Masud, F. Bostan, C. E. Pass, S. Samir, H. Stuebing et al., Recombinant Factor VIIa Treatment of Severe Bleeding in Cardiac Surgery Patients: A Retrospective Analysis of Dosing, Efficacy, and Safety Outcomes, Journal of Cardiothoracic and Vascular Anesthesia, vol.23, issue.1, pp.28-33, 2009.
DOI : 10.1053/j.jvca.2008.08.003

J. Vincent, R. Rossaint, B. Riou, Y. Ozier, D. Zideman et al., Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective, Critical Care, vol.10, issue.4, p.120, 2006.
DOI : 10.1186/cc5026

J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kohl et al., Guideline on antiplatelet and anticoagulation management in cardiac surgery, European Journal of Cardio-Thoracic Surgery, vol.35, issue.5, pp.73-92, 2008.
DOI : 10.1016/S0735-1097(00)00521-0

S. Bélisle and J. Hardy, Hemorrhage and the Use of Blood Products After Adult Cardiac Operations: Myths and Realities, The Annals of Thoracic Surgery, vol.62, issue.6, pp.1908-1917, 1996.
DOI : 10.1016/S0003-4975(96)00944-7

K. Karkouti, W. Beattie, D. Wijeysundera, T. Yau, S. Mccluskey et al., Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis, Transfusion, vol.93, issue.1, pp.26-34, 2005.
DOI : 10.1111/j.1537-2995.2004.04144.x

C. Willis, R. Bird, D. Mullany, P. Cameron, and L. Phillips, Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes, Vox Sanguinis, vol.33, issue.4, pp.531-537, 2010.
DOI : 10.1111/j.1423-0410.2009.01276.x

K. Karkouti, T. Yau, S. Riazi, K. Dattilo, M. Wasowicz et al., Les d??terminants de complications avec le facteur VIIa recombinant utilis?? pour les pertes sanguines r??fractaires en chirurgie cardiaque, Canadian Journal of Anesthesia, vol.95, issue.Suppl 1, pp.802-809, 2006.
DOI : 10.1161/01.CIR.97.6.562

O. Connell, K. Wood, J. Wise, R. Lozier, J. Braun et al., Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa, JAMA, vol.295, issue.3, pp.293-298, 2006.
DOI : 10.1001/jama.295.3.293

H. Roberts, Recombinant factor VIIa (NovoSeven??) and the safety of treatment, Seminars in Hematology, vol.38, pp.48-50, 2001.
DOI : 10.1016/S0037-1963(01)90148-9

C. Von-heymann, U. Redlich, U. Jain, M. Kastrup, T. Schroeder et al., Recombinant activated factor VII for refractory bleeding after cardiac surgery???A retrospective analysis of safety and efficacy, Critical Care Medicine, vol.33, issue.10, pp.2241-2246, 2005.
DOI : 10.1097/01.CCM.0000181527.47749.57

P. Marik, L. Andrews, and B. Maini, The Incidence of Deep Venous Thrombosis in ICU Patients, Chest, vol.111, issue.3, pp.661-664, 1997.
DOI : 10.1378/chest.111.3.661

M. Taylor, Recombinant factor seven therapy for postoperative bleeding in neonatal and pediatric cardiac surgery, Ann Thorac Surg, vol.84, pp.161-168, 2007.

M. Gandhi, R. Pierce, L. Zhang, M. Moon, G. Despotis et al., Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant, Journal of Cardiothoracic Surgery, vol.20, issue.4, p.32, 2007.
DOI : 10.1053/j.jvca.2005.06.005

A. Rastan, N. Lachmann, T. Walther, N. Doll, T. Gradistanac et al., Autopsy Findings in Patients on Postcardiotomy Extracorporeal Membrane Oxygenation (ECMO), The International Journal of Artificial Organs, vol.78, issue.12, pp.1121-1131, 2006.
DOI : 10.1136/hrt.78.1.34

S. Schenk, A. El-banayosy, W. Prohaska, L. Arusoglu, M. Morshuis et al., Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support, The Journal of Thoracic and Cardiovascular Surgery, vol.131, issue.6, pp.1373-1381, 2006.
DOI : 10.1016/j.jtcvs.2006.01.048

M. Dlxand, A. Godier, !. Véforoqoo-note, M. , T. Lecompte-bociili-'..... et al., Hacquard, O livier CoIl i900nJnd ud obje<:ti>. R8eoob<nanIPI' lot uocon'I"oIlod and iJ bI-*og ,oIalOd ' 0 macro~

M. Sio1-)-'mole-n_-z8a1and, _. _. , A. @bullet-_-_, and _. Lof-)-'.., 01 and 80 and 2OO,.g Ioq-' rfVIla g<oopa In _ lO onimolo. iadalOd ,;gIn CMd. ah an III-<> "a, Im ....... Al 5mn

". .. Ee_-"-r, . Th, . .. _-"-ii-ru, . Mou-10,-roi-g<oop, . M. Foi et al., g>I ~1y,~'cn, Nm'o Nordi,k. II.:!V,'.c[(l Iknm,lk ) wos fi", dc,-clorcd h [hc Irc .. mcn[ of 'p<>n"neo,, 01 ic blccding in h.cmophili.c l''''icn, ' The ,i", .. c f.c [m (l T ) .Cli".lCd f.clO[ \'11 ( r \'l b) compla ini,i .. ion of foCIO'" X .nd IX, [he[cby p[om"'ing [h[omb in gcnc,"ion.'" H igh n'Ih concenu .. io", [cpor'cdly .Cli,~,c f.clO[ X in ? Tr .i ",kpcndcn[ and pb[dcHlcrc",kn[ mmne[! 'Il" ... Ir \' lb ;. gcncn'cd ... i["" of T r c'I, oc,.p<

-. Iy, .. .. Modion-blood, T. .. Orm<.-'ino, _. Cmco-", 01. .. 1_ et al., 56 min I,angoo 7-60 minj, 15 mn I .... go 5-60mn) and 10 min l' ... go 5 -60mn) _ . 22.5 g i'angoo 1_ &8\/1, 12 g rangoo 0-36\11 and 5 g rangoo 0-31 \/1. ah>nor in ... rfVIla g O<Jpo. Viauol i 1 -' Coftclllsioft Recanbinanl Mlaa' 8001 2OO,.g Ioq-' promooed , .... aealng 01 a I",go and alig..y~, Iton ....gical "'

@. Riou, . @bullet-in, !. Co, and I. , inc[=ingly becn1 "sc,lled [rial. bd. '" '0 coneh~k [I»[ [he dfoc· ,i,-cne» of [n'Ih "" ? I»cic dmg [cm .in. "nclc .. '''' I."gc ·p<>,<o[cd ",,!omi,cd .nl<!ics .. c diffi· c"h ID pc[fomo fOI.n cmc[gc""y, m.king 'Y'lCm"ic ob'! '1UIpi. diffic"h Tl1c", finding. highliglH [hc necd for [hc ptoof of conccpt of [r \'l h cffic.cy in [cptod,>cibly i"jUlC<! .nim.l ? Wc hypcohe.izcd [I»[ [. '\'I h oo"ld bc ">c<! in [he m.lUgcrncn[ of ? mgC[y or>[cm c"cn [oo"gh i, ;' compk[cly DOmo.l, 'l'hi. 'he~[y i ? no, lus ~nera [cd .n immcdi.1C necd fOI ph can..,[ he con[rollcd by [he I»cmpidly naibblc (u'OIm .) or when '''[gC[y m.y he .... rmful fOI d>e l''' 'icnl (<bm.g~ COI'I uol~ " W~ .,.um~d , .... ,h~ b

@. Wc-desigd, I. Coio, J. Cd, L. "-lin~-wirh-europe, and . Li, c "bbi ~ '" ,h i< .nim.1 i, <O,~ pc,form~d .f"" U C3 ,m~n, injectio" to

H. B<-prf-of-conccpr, p '~m ic .dminiw>!i

H. Anim and . Ethi, mk. of ,b< 'J""it R«hc,cb< Méd· icak ' in F, rul ,le 1. S""é~

. Rabbiismgkg-'kc and . Mi, ,~r~ .n:rc"b< ,i,<:<I wi,h. mixhH~ of kc, IRIIAC Sm, 1000.

. Anim, C. Le, @. Il, . =1-'i, ~. G~rm et al., 'g<:1'I, ( ;crm Abbot~ Af"". local .ruc<tb< ,ic ( 1 ml ' .c , lidocai"C ncc) ""'" prm'i,lcr~ ? m~di neck inci,ion perform~d to ~",u,~ m«h· .nical 1,~ntil>!iOl'l ('~'pir.to,.; ""e, 4S c.,.ck.min-' ; ,idol ,'oh,m~, S mlkg-' ~ \'cntil.,i,m lbli<b<d '0 m.in .. i" phpiological pH and o'.,.gcngc of 38 _ 385'(; u,i"g.n cJ«,ric bb"kc, (m~dium bbnkct.p,~m~ col· lec",d .nd rr~ .. ~d wi,h. monitoring ? .,."~m (Acqkno",. k dgc 3.7; lI iop>c, Califomia, USA) .nd a l'C (l',~ .. ri,; Coml"'q, Californi., USA ~ F'l'otoc:oI d Hign Tb< ca,or id bion ,hc blccd cob< :!C h~m" icof ,b< p",rocoI ,Ie,ign .. c ,bo"" in F ig, l ' l 'b< ,or.1 kng< h of ,h~ righ, common ca,orid,1 b'ge break of ,h~, rumic moni,oringb< ,h )~oirhl b",nch, m,!k· ing ,he b<ginning of The .i", of ,b< ca

~. Tb<, I. .. , ~. ~. , and M. .. Bdor~, prior 1"li· d .. ion ,;,h ? [lopple, con,ro ~ ,b< coo.cn wcigh he,"y ~nough '0 prOl'i,1e .ppmpri cmollhogc, bi" ligh ' cnough '0 m.i" ... in blo"d ilo~ for 1 h by qllickJo; and gcnrly ,~m"';"g .",1 pbci"g ,h~ g:r'uc In~ g:r'uc Inlk, uc Inllugh ,b< w»cL 8lecding "..,. ,'i" .. lIy con u olkd c.ch minuft~, rr~ .. m~", . dm ini 1I ~11. ) J ."d .. ,b< ~"d of, pp.1-1

@. Aft~ and . S-min-obsc~-blccding, for Iyop hilizcd dmg) or 10 01 200 j.lgkg-' ,F \'I h in ,b< Id, m"gin.1 ea, l'~in. Tb< uea,m~n' .IiquorrI fr",c" bdorc ,b< b<gi"ni"g of ,he ,mdy , ' In~ i",·c"ig bli",lcd '" ,b< rr~ .. m~", group Wb<n ,b< cam,id .toppcd blccding,b< l im~ ... u oo,~d ."d ,b< 1'~»c1 "..,. lef, unrol'~,~d until ,b< ~",1 of ,h~ ~'perim~nL J" ,b< ""'" of blccding ,eculI~"ce, ",hich occurr~ d in .ix "bbi,.,b< g:rlllC, ~-" . -. . ~ ... -. .00 .... -·

O. D. Os and C. , .[;'o", t.c",'ccn d""gc glOups WC[C pc[fmrncd ,,;ng 1V, 9S.h l'Crcc

M. The-mcmoglohin-k,-d and . Clc, cri. 1 pH! [cmI'C"""c [cm.i""d "i[hi" phpiological ""gcs [h">ugoo,, [t.c c"l'C[imCM' in [t.c ,h[cc groups The mco, cl" fOI pb[cIc[ coun[ (r. bk 1)

2. Blhd-du, [. !. S6mi, and . 2oo, gkg-' [n'lb glOups, [hc mcdigc 7_ 60 min), 1 S mi. gc S_ 60 mi,) . "d 1 0 mi" ("mgc S_ 60 min), [c'I'cc'· iI'cly, bUl no "oti"ically .ignifican[ diffc[c"cc w'"" fOI''''! t.c'wccn [t.c 8O WC[C "ill bkcdi"g ot ,t.c c"d of ,hc c'I'C[imC"L i"ch,!i"g "i"" i" [hc whick group C3ch [n'lb pOl'p. Al[oough [t.c p[ci"joo'io" 1I~1[' di<! !>O[ diffc[ . m""g [t.c [h!<Oc group' (d of [hc 80, ignificandy highc[ [Mn [M[ of [t.c 80 01 200,...gkg-' [n'lb glOups ( Figgkg-' [F\"II. group . nim.l

P. , E. I. >o-'cdic, . Nolpi, 8. Tt, !. Ili et al., minotion ofhc[ · mOlc Discussion ln [hi,d 10 conuol . n in"'ct. bk bkcd,copic 01 micgkg-' dMc >ccmcd 111gC C1>Ol'gh ID fcd bc[,<ocn [t.c 80.g kg -, dose., Too", k!>Owlcdgc, [hi. i. [toc fi,[ ,imc [M[ [F\"Il> lus bccn ,00 10 bc cffccti,<o in ucoting ,~'C[C . nc[i11 blccd, in . t.c. lthy "bhit modcl "i,hOl" [c"""i",i"" 01 blood dilu,ion. Thi. [cs"l[ """ obt. ine<' "i,h [t.c l,~!ic<l which i ? ? imil cricc, ba5cd "" [hc 1''1' dOO[ca5C . nd H'II . ctil'i.,'ccn . nim.l Th~ [y dCI'C",!ing on [t.c . nim.l 'l'Ccic ? . As m l1C pc[fmrncd "i[h .. bhi, bt. in [hlOmbopb>'in [toc choice ofbhi[ modd >ccmbl;'he<! l'''''I'Ccti!"C ,ri. l of h"m.g kg -, [F\"Il> [e<Io>ce<! bloo<! ru. only in [hc ca>c of bhm Cill "al1;O l'',bli,he<! [t.c ""ly kM"" "ndomiw! conuolkd [ri. l fOI [F\"II. in ",[di1c '''[gcr;, Aktoo"gh [hc [cs"h. WC[C cn""'mging. [toci[ cooch"ion w ,;c"<od wi,hin [toc con[c" of ,toc limi .. ,io", of [toc rond,>c'cd in ",bbi, cc of uC1,mcnt· [cb Ttocil d Thc !=clinc 1''1' w C01gul .. ion lus '0 toc impro"cd wi, pp.5-5, 2009.

M. Marietta, L. Facchini, P. Pedrazzi, S. Busani, and G. Torelli, Pathophysiology of Bleeding in Surgery, Transplantation Proceedings, vol.38, issue.3, pp.812-816, 2006.
DOI : 10.1016/j.transproceed.2006.01.047

P. Mannucci and M. Levi, Prevention and Treatment of Major Blood Loss, New England Journal of Medicine, vol.356, issue.22, pp.2301-2312, 2007.
DOI : 10.1056/NEJMra067742

O. Hein, J. Birnbaum, K. Wernecke, W. Konertz, U. Jain et al., Three-year survival after four major post???cardiac operative complications*, Critical Care Medicine, vol.34, issue.11, pp.2729-2766, 2006.
DOI : 10.1097/01.CCM.0000242519.71319.AD

U. Hedner and W. Kisiel, Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors., Journal of Clinical Investigation, vol.71, issue.6, pp.1836-1877, 1983.
DOI : 10.1172/JCI110939

G. Majumdar, J. Phillips, H. Lavallee, and G. Savidge, Acquired haemophilia in association with Type III von Willebrand??s disease, Blood Coagulation & Fibrinolysis, vol.4, issue.6, pp.1035-1042, 1993.
DOI : 10.1097/00001721-199304060-00020

J. Castel, D. Hedner, U. Hess, and J. , Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries, J Trauma, vol.50, pp.721-730, 2001.

U. Hedner, Recombinant activated factor VII as a universal haemostatic agent, Blood Coagul Fibrinolysis, vol.9, issue.1, pp.147-52, 1998.

A. Liem, D. Biesma, S. Ernst, and A. Schepens, Recombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms, Thromb Haemost, vol.82, pp.150-151, 1999.

J. Hardy, S. Belisle, and P. Van-der-linden, Efficacy and safety of activated recombinant factor VII in cardiac surgical patients, Current Opinion in Anaesthesiology, vol.22, issue.1, pp.95-104, 2009.
DOI : 10.1097/ACO.0b013e32831a40a3

E. Tuddenham, S. Pemberton, and D. Cooper, Inherited factor VII deficiency: genetics and molecular pathology, Thromb Haemost, vol.74, pp.313-334, 1995.

T. Drake, J. Morrissey, and T. Edgington, Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis, Am J Pathol, vol.134, pp.1087-97, 1989.

J. Himber, M. Riederer, and Y. Nemerson, Blood-borne tissue factor: another view of thrombosis

E. Davie, K. Fujikawa, and W. Kisiel, The coagulation cascade: initiation, maintenance, and regulation, Biochemistry, vol.30, issue.43, pp.10363-70, 1991.
DOI : 10.1021/bi00107a001

R. Macfarlane, An Enzyme Cascade in the Blood Clotting Mechanism and its Function as a Biochemical Amplifier, Nature, vol.9, issue.4931, pp.498-507, 1964.
DOI : 10.1042/bj0840062

E. Davie and O. Ratnoff, Waterfall Sequence for Intrinsic Blood Clotting, Science, vol.145, issue.3638, pp.1310-1312, 1964.
DOI : 10.1126/science.145.3638.1310

D. Monroe and M. Hoffman, What Does It Take to Make the Perfect Clot?, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.26, issue.1, pp.41-49, 2006.
DOI : 10.1161/01.ATV.0000193624.28251.83

M. Kisiel, W. Kurachi, and K. , Characterization of a cDNA coding for human factor VII, Proc Natl Acad Sci U S A, vol.83, issue.20, pp.2412-2418, 1986.

T. Abshire and G. Kenet, Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors, Journal of Thrombosis and Haemostasis, vol.83, issue.6, pp.899-909, 2004.
DOI : 10.1046/j.1365-2516.2002.00532.x

C. Van-'t-veer, N. Golden, and K. Mann, Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa, Blood, vol.95, pp.1330-1335, 2000.

T. Lisman, L. Mosnier, T. Lambert, E. Mauser-bunschoten, J. Meijers et al., Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A, Blood, vol.99, issue.1, pp.175-184, 2002.
DOI : 10.1182/blood.V99.1.175

P. Sié, Mécanisme d'action pro-hémostatique du facteur VIIa recombinant

J. Reichert and C. Paquette, Therapeutic recombinant proteins: trends in US approvals, Curr Opin Mol Ther, vol.5, pp.139-186, 1982.

T. Lisman, S. Moschatsis, J. Adelmeijer, H. Nieuwenhuis, D. Groot et al., Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3

T. Lisman, J. Adelmeijer, H. Heijnen, and P. De-groot, Recombinant factor VIIa restores aggregation of ??IIb??3-deficient platelets via tissue factor-independent fibrin generation, Blood, vol.103, issue.5, pp.1720-1727, 2004.
DOI : 10.1182/blood-2003-07-2287

M. Durand, T. Lecompte, M. Hacquard, and J. Carteaux, Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade, European Journal of Cardio-Thoracic Surgery, vol.34, issue.3, pp.687-696, 2008.
DOI : 10.1016/j.ejcts.2008.05.029

C. Weeterings, P. De-groot, J. Adelmeijer, and T. Lisman, The glycoprotein Ib-IX-V complex contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface, Blood, vol.112, issue.8, pp.3227-3260, 2008.
DOI : 10.1182/blood-2008-02-139113

A. Kendall and L. Lowenstein, Alterations in blood coagulation and hemostasis during extracorporeal circulation. I, Can Med Assoc J, vol.87, pp.786-90, 1962.

A. Kendall and L. Lowenstein, Alterations in blood coagulation and hemostasis during extracorporeal circulation. II, Can Med Assoc J, vol.87, pp.859-64, 1962.

L. Phillips, J. Malm, R. Deterling, and J. , Coagulation Defects Following Extracorporeal Circulation, Annals of Surgery, vol.157, issue.3, pp.317-343, 1963.
DOI : 10.1097/00000658-196303000-00001

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1466400/pdf

B. Hunt, R. Parratt, H. Segal, S. Sheikh, P. Kallis et al., Activation of Coagulation and Fibrinolysis During Cardiothoracic Operations, The Annals of Thoracic Surgery, vol.65, issue.3, pp.712-720, 1998.
DOI : 10.1016/S0003-4975(97)01345-3

M. Weiss, J. Yver, M. Samama, and C. Dubost, Effets dissociés d'un nouvel antifibrinolytique (acide epsilon-amino-caproïque) injecté in vivo sur les épreuves in vitro de fibrinolyse, Presse Méd, vol.71, pp.1879-80, 1963.

I. Gouin, T. Lecompte, M. Morel, J. Lebrazi, P. Modderman et al., In vitro effect of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis, Circulation, vol.85, issue.3, pp.935-976, 1992.
DOI : 10.1161/01.CIR.85.3.935

H. Lu, C. Soria, H. Li, J. Soria, H. Lijnen et al., Role of active center and lysine binding sites of plasmin in plasmin-induced platelet activation and disaggregation

C. Soria, Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with and without aprotinin therapy, Thromb Haemost, vol.72, pp.438-481, 1994.

T. Lecompte, J. Carteaux, V. Regnault, D. Maistre, E. Collet et al., Is it possible and worth to use another anticoagulant than (unfractionated) heparin during cardiopulmonary bypass for cardiac surgery?, ITBM-RBM, vol.24, pp.45-53, 2003.

J. George, Platelet surface glycoproteins. Studies on resting and activated platelets and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery., Journal of Clinical Investigation, vol.78, issue.2, pp.340-348, 1986.
DOI : 10.1172/JCI112582

D. Somer and F. , Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass, The Journal of Thoracic and Cardiovascular Surgery, vol.123, issue.5, pp.951-959, 2002.
DOI : 10.1067/mtc.2002.120334

G. Despotis, C. Eby, and D. Lublin, A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery, Transfusion, vol.73, issue.5, pp.2-30, 2008.
DOI : 10.1053/jcan.2002.126927

T. Mochizuki, P. Olson, F. Szlam, J. Ramsay, and J. Levy, Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass, Anesth Analg, vol.87, pp.781-786, 1998.

J. Kirklin, Cardiac surgery. Sons JWa, editor

S. Belisle and J. Hardy, Hemorrhage and the Use of Blood Products After Adult Cardiac Operations: Myths and Realities, The Annals of Thoracic Surgery, vol.62, issue.6, pp.1908-1925, 1996.
DOI : 10.1016/S0003-4975(96)00944-7

Y. Deng, K. Byth, and H. Paterson, Age and Left Ventricular Impairment Predict Reopening for Bleeding, Asian Cardiovascular and Thoracic Annals, vol.75, issue.2, pp.147-52, 2003.
DOI : 10.1016/0003-4975(93)91140-I

M. Crowther and T. Warkentin, Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents, Journal of Thrombosis and Haemostasis, vol.61, issue.Suppl. 1, pp.107-117, 2009.
DOI : 10.1111/j.1538-7836.2009.03429.x

D. Mahieu-caputo, M. Hurtaud-roux, M. Huisse, M. Denninger, and D. De-prost, The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage, J Thromb Haemost, vol.5, pp.266-73, 2007.

H. Hemker, P. Giesen, M. Ramjee, R. Wagenvoord, and S. Beguin, The thrombogram: monitoring thrombin generation in platelet-rich plasma, Thromb Haemost, vol.83, pp.589-91, 2000.

G. Tucci and F. Tomai, [the Use of Thromboelastography in the Study of Blood Coagulation during Extracorporeal Circulation. Preliminary Contribution, Ann Ital Chir, vol.40, pp.1112-1141, 1963.

M. Wasowicz, M. Meineri, S. Mccluskey, N. Mitsakakis, and K. Karkouti, The Utility of Thromboelastography for Guiding Recombinant Activated Factor VII Therapy for Refractory Hemorrhage After Cardiac Surgery, Journal of Cardiothoracic and Vascular Anesthesia, vol.23, issue.6, 2009.
DOI : 10.1053/j.jvca.2009.03.012

E. Mammen, R. Alshameeri, and P. Comp, Preliminary Data from a Field Trial of the PFA-100??? System, Seminars in Thrombosis and Hemostasis, vol.21, issue.S 02, pp.113-134, 1995.
DOI : 10.1055/s-0032-1313613

U. Alstrom, F. Granath, J. Oldgren, E. Stahle, H. Tyden et al., Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery, Thrombosis Research, vol.124, issue.5, 2009.
DOI : 10.1016/j.thromres.2009.06.024

D. Ngaage and J. Bland, Lessons from aprotinin: is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies, European Journal of Cardio-Thoracic Surgery, vol.9, issue.1, pp.1375-83
DOI : 10.1510/icvts.2008.198325

A. Laupacis and D. Fergusson, Drugs to Minimize Perioperative Blood Loss in Cardiac Surgery, Anesthesia & Analgesia, vol.85, issue.6, pp.1258-67, 1997.
DOI : 10.1213/00000539-199712000-00014

Y. Ozier and S. Schlumberger, Approches pharmacologiques de r??duction des pertes sanguines et des transfusions en chirurgie, Canadian Journal of Anesthesia/Journal canadien d'anesth??sie, vol.94, issue.1, pp.21-30, 2006.
DOI : 10.1111/j.1537-2995.2005.00204.x

G. Pernod, A. Godier, C. Gozalo, B. Tremey, and P. Sie, French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding), Thrombosis Research, vol.126, issue.3, pp.167-74
DOI : 10.1016/j.thromres.2010.06.017

D. Bruce and T. Nokes, Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital, Critical Care, vol.12, issue.4, p.105, 2008.
DOI : 10.1186/cc6987

A. Godier, S. Susen, and C. Samama, Treatment of massive bleeding with prothrombin complex concentrate: argument against, Journal of Thrombosis and Haemostasis, vol.97, issue.12
DOI : 10.1111/j.1538-7836.2010.04062.x

J. Carteaux and T. Lecompte, Recombinant activated factor VII attenuates major arterial bleeding in noncoagulopathic rabbits, Eur J Anaesthesiol

D. Mangano, I. Tudor, and C. Dietzel, The Risk Associated with Aprotinin in Cardiac Surgery, New England Journal of Medicine, vol.354, issue.4, pp.353-65, 2006.
DOI : 10.1056/NEJMoa051379

P. Duke, R. Arellano, M. Blajchman, J. Bussieres, D. Cote et al., A comparison of aprotinin and lysine analogues in high-risk cardiac surgery, N Engl J Med, vol.358, pp.2319-2350, 2008.

M. Poon and R. Oiron, Recombinant activated factor VII (NovoSeven??) treatment of platelet-related bleeding disorders, Blood Coagulation & Fibrinolysis, vol.11, issue.1, pp.55-68, 2000.
DOI : 10.1097/00001721-200004001-00013

J. Vincent, R. Rossaint, B. Riou, Y. Ozier, D. Zideman et al., Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective, Critical Care, vol.10, issue.4, p.120, 2006.
DOI : 10.1186/cc5026

J. Kratz, J. Toole, F. Crawford, J. Ikonomidis, and J. , Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery, Ann Thorac Surg, vol.85, pp.1669-76, 2008.

J. Siller-matula, R. Plasenzotti, A. Spiel, P. Quehenberger, and B. Jilma, Summary, Thrombosis and Haemostasis, vol.100, issue.09, pp.397-404, 2008.
DOI : 10.1160/TH08-02-0103

P. Golino, G. Ambrosio, I. Pascucci, M. Ragni, E. Russolillo et al., Experimental carotid stenosis and endothelial injury in the rabbit: an in vivo model to study intravascular platelet aggregation, Thromb Haemost, vol.67, pp.302-307, 1992.

A. Godier, E. Mazoyer, F. Cymbalista, M. Cupa, and C. Samama, Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study, Journal of Thrombosis and Haemostasis, vol.295, issue.2, pp.244-253, 2007.
DOI : 10.1097/00001721-200004001-00006

S. Charbonneau, F. Girard, D. Boudreault, M. Ruel, N. Blais et al., Summary, Thrombosis and Haemostasis, vol.97, issue.02, pp.296-303, 2007.
DOI : 10.1160/TH06-08-0429

J. Carteaux, A. Gast, T. Tschopp, and S. Roux, Activated Clotting Time as an Appropriate Test to Compare Heparin and Direct Thrombin Inhibitors Such as Hirudin or Ro 46-6240 in Experimental Arterial Thrombosis, Circulation, vol.91, issue.5, pp.1568-74, 1995.
DOI : 10.1161/01.CIR.91.5.1568

P. Viars, J. Caen, and L. Drouet, Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig, Thromb Haemost, vol.68, pp.500-505, 1992.

S. Hanson and L. Harker, Baboon models of acute arterial thrombosis, Thromb Haemost, vol.58, pp.801-806, 1987.

S. Roux, J. Carteaux, P. Hess, L. Falivene, and J. Clozel, Experimental carotid thrombosis in the guinea pig, Thromb Haemost, vol.71, pp.252-258, 1994.

J. Folts, An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis, Circulation, vol.83, pp.3-14, 1991.

J. Himber, D. Kirchhofer, M. Riederer, T. Tschopp, B. Steiner et al., Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function, Thromb Haemost, vol.78, pp.1142-1151, 1997.

P. Coriat, Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding

A. Godier, C. Flaujac, M. Horellou, D. Mesmay, M. Becanne et al., Argatroban and renal replacement therapy in a morbidly obese patient with heparin-induced thrombocytopenia: A case report, Thrombosis Research, vol.126, issue.2, pp.141-144
DOI : 10.1016/j.thromres.2009.12.018

J. Dellamonica, E. Mazoyer, J. Rosa, F. Cymbalista, and C. Samama, Abrupt oxygen decrease influences thrombosis and bleeding in stenosed and endothelium-injured rabbit carotid arteries, European Journal of Anaesthesiology, vol.25, issue.12, pp.1002-1010, 2008.
DOI : 10.1017/S0265021508004390

J. Sondeen, A. Pusateri, U. Hedner, L. Yantis, and J. Holcomb, RECOMBINANT FACTOR VIIa INCREASES THE PRESSURE AT WHICH REBLEEDING OCCURS IN PORCINE UNCONTROLLED AORTIC HEMORRHAGE MODEL, Shock, vol.22, issue.2, pp.163-171, 2004.
DOI : 10.1097/01.shk.0000129202.76706.bd

W. Sapsford, S. Watts, G. Cooper, and E. Kirkman, Recombinant Activated Factor VII Increases Survival Time in a Model of Incompressible Arterial Hemorrhage in the Anesthetized Pig, The Journal of Trauma: Injury, Infection, and Critical Care, vol.62, issue.4, pp.868-79, 2007.
DOI : 10.1097/ta.0b013e318034204b

S. Stanworth, J. Birchall, C. Doree, and C. Hyde, Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia, Cochrane Database Syst Rev, 2007.

P. Diprose, M. Herbertson, O. Shaughnessy, D. Gill, and R. , Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study, British Journal of Anaesthesia, vol.95, issue.5, pp.596-602, 2005.
DOI : 10.1093/bja/aei244

H. Ekert, C. Brizard, R. Eyers, A. Cochrane, and R. Henning, Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: a randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy, Blood Coagulation & Fibrinolysis, vol.17, issue.5, pp.389-95, 2006.
DOI : 10.1097/01.mbc.0000233369.03358.c1

R. Gill, M. Herbertson, A. Vuylsteke, P. Olsen, C. Von-heymann et al., Safety and Efficacy of Recombinant Activated Factor VII: A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery, Circulation, vol.120, issue.1
DOI : 10.1161/CIRCULATIONAHA.108.834275

L. Blackbourne and J. Holcomb, Use of recombinant factor VIIa in US military casualties for a five-year period, J Trauma, vol.69, pp.353-362

B. Donahue, D. Gailani, and A. Mast, Disposition of tissue factor pathway inhibitor during cardiopulmonary bypass, Journal of Thrombosis and Haemostasis, vol.80, issue.1, pp.1011-1017, 2006.
DOI : 10.1182/blood-2004-09-3422

T. Hackeng, L. Maurissen, E. Castoldi, and J. Rosing, Regulation of TFPI function by protein S, Journal of Thrombosis and Haemostasis, vol.6, issue.1, pp.165-173, 2009.
DOI : 10.1111/j.1538-7836.2009.03363.x

A. Kastrati and I. Ott, Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction, Thromb J, vol.7, p.11, 2009.

O. Warren, A. Darzi, and T. Athanasiou, Recombinant activated factor VII in cardiac surgery ??? first, do no harm, Journal of Cardiothoracic Surgery, vol.104, issue.13, p.50, 2007.
DOI : 10.1182/blood-2004-06-2223

A. Dziatkowiak, Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device, J Thorac Cardiovasc Surg, vol.123, pp.384-389, 2002.

E. Potapov, M. Pasic, M. Bauer, and R. Hetzer, Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device, The Annals of Thoracic Surgery, vol.74, issue.6, pp.2182-2185, 2002.
DOI : 10.1016/S0003-4975(02)04105-X

B. Vidne and G. Sahar, Use of recombinant factor VII to control bleeding in a patient supported by right ventricular assist device after heart transplantation, J Heart Lung Transplant, vol.24, pp.347-356, 2005.

J. Flynn, P. Camp, J. Jahania, M. Ramaiah, C. Akers et al., Successful Treatment of Refractory Bleeding After Bridging from Acute to Chronic Left Ventricular Assist Device Support with Recombinant Activated Factor VII, ASAIO Journal, vol.50, issue.5, pp.519-540, 2004.
DOI : 10.1097/01.MAT.0000136516.16726.35

D. Heise, A. Brauer, and M. Quintel, Recombinant activated factor VII (Novo7??) in patients with ventricular assist devices: Case report and review of the current literature, Journal of Cardiothoracic Surgery, vol.86, issue.2, p.47, 2007.
DOI : 10.1111/j.0042-9007.2004.00393.x

T. Syburra, M. Lachat, M. Genoni, and M. Wilhelm, Fatal Outcome of Recombinant Factor VIIa in Heart Transplantation With Extracorporeal Membrane Oxygenation, The Annals of Thoracic Surgery, vol.89, issue.5, pp.1643-1648
DOI : 10.1016/j.athoracsur.2009.09.039

J. Bui, G. Despotis, E. Trulock, G. Patterson, and L. Goodnough, Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII, The Journal of Thoracic and Cardiovascular Surgery, vol.124, issue.4, pp.852-856, 2002.
DOI : 10.1067/mtc.2002.126038

O. Connell, K. Wood, J. Wise, R. Lozier, J. Braun et al., Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa, JAMA, vol.295, issue.3, pp.293-301, 2006.
DOI : 10.1001/jama.295.3.293

M. Gandhi, R. Pierce, L. Zhang, M. Moon, G. Despotis et al., Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant, Journal of Cardiothoracic Surgery, vol.20, issue.4, p.32, 2007.
DOI : 10.1053/j.jvca.2005.06.005

P. Allison, D. Cooley, I. Gregoric, and O. Frazier, High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII, J Heart Lung Transplant, vol.28, pp.785-90, 2009.

S. Chumnanvej, M. Wood, T. Macgillivray, and M. Melo, Perioperative Echocardiographic Examination for Ventricular Assist Device Implantation, Anesthesia & Analgesia, vol.105, issue.3, pp.583-601, 2007.
DOI : 10.1213/01.ane.0000278088.22952.82

F. Masud, F. Bostan, C. E. Pass, S. Samir, H. Stuebing et al., Recombinant Factor VIIa Treatment of Severe Bleeding in Cardiac Surgery Patients: A Retrospective Analysis of Dosing, Efficacy, and Safety Outcomes, Journal of Cardiothoracic and Vascular Anesthesia, vol.23, issue.1, pp.28-33, 2009.
DOI : 10.1053/j.jvca.2008.08.003

M. Tranholm, R. Rojkjaer, C. Pyke, A. Kristensen, B. Klitgaard et al., Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits, Thrombosis Research, vol.109, issue.4
DOI : 10.1016/S0049-3848(03)00146-4

C. Samama, Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits, Can J Anaesth, vol.51, pp.672-681, 2004.

S. Chan, M. Kong, D. Minning, U. Hedner, and V. Marder, Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin, Journal of Thrombosis and Haemostasis, vol.10, issue.4
DOI : 10.1097/00001721-199912000-00010

M. Fridberg, U. Hedner, H. Roberts, and E. Erhardtsen, A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects, Blood Coagulation & Fibrinolysis, vol.16, issue.4
DOI : 10.1097/01.mbc.0000169218.15926.34

L. Vilchez, I. , J. Hedner, U. Altisent, C. Escolar et al., Traffic of rFVIIa through Endothelial Cells and Redistribution into Subendothelium: Implications for a Prolonged Hemostatic Effect, Journal of Coagulation Disorders, 2009.

D. Stainsby, S. Maclennan, D. Thomas, J. Isaac, and P. Hamilton, Management of massive blood loss: a template guideline, British Journal of Anaesthesia, vol.85, issue.3, pp.634-675, 2006.
DOI : 10.1093/bja/85.3.487

C. Samama, Prothrombin complex concentrates: a brief review, European Journal of Anaesthesiology, vol.25, issue.10, pp.784-793, 2008.
DOI : 10.1017/S0265021508004675

M. Moulton, L. Creswell, M. Mackey, J. Cox, and M. Rosenbloom, Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations, The Journal of Thoracic and Cardiovascular Surgery, vol.111, issue.5, pp.1037-1083, 1996.
DOI : 10.1016/S0022-5223(96)70380-X